Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s15010-021-01651-4 http://scihub22266oqcxt.onion/10.1007/s15010-021-01651-4 34213733!8249824!34213733     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Infection 2021 ; 49 (5): 1045-1048 Nephropedia Template TP {{tp|p=34213733|t=2021. IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection |pdf=|usr=}}{{34213733}} gab.com Text IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection JO: Infection http://www.kidney.de/pget.php?&tw=1&pmid=34213733 #FOAvip OBJECTIVES: Coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. Study of dynamicity and durability of naturally developed antibodies against SARS-CoV-2 are of great importance from an epidemiological viewpoint. METHODS: In this observational cohort study, we have followed up the 76 individuals who tested positive for SARS-CoV-2 infection by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) for 16 weeks (post-enrolment) to record the periodic changes in titre, concentration, clinical growth and persistence of naturally developed SARS-CoV-2 antibodies. We collected serum samples from these individuals for 16 weeks with a frequency of weekly and fortnightly during each follow-up and tested them in two CLIA-based platforms (Abbott Architect i1000SR and Roche Cobas e411) for testing SARS-CoV-2 antibodies both qualitatively and quantitatively. RESULTS: We recorded the antibody magnitude of these individuals 10 times between September 2020 and February 2021. We found a waning of antibodies against nucleocapsid antigen protein but not a complete disappearance by the end of 16 weeks. Out of 76 cases, 30 cases (39.47%) became seronegative in qualitative assay, although all the sera samples (100%) remained positive when tested in quantitative assay. CONCLUSION: The lower persistence of anti-nucleocapsid SARS-CoV-2 antibody may not be the exact phenomenon as those cases were still seropositive against spike protein and help in neutralising the virus. Twit Text FOAVip IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection ????Infection http://www.kidney.de/pget.php?&tw=1&pmid=34213733 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34213733 #FOAvip English Wikipedia <ref>{{Cite pmid|34213733}}</ref> IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection #MMPMID34213733 Choudhary HR; Parai D; Dash GC; Peter A; Sahoo SK; Pattnaik M; Rout UK; Nanda RR; Pati S; Bhattacharya D Infection 2021[Oct]; 49 (5): 1045-1048 PMID34213733show ga OBJECTIVES: Coronavirus disease-19 (COVID-19) pandemic became the greatest public health challenge globally. Study of dynamicity and durability of naturally developed antibodies against SARS-CoV-2 are of great importance from an epidemiological viewpoint. METHODS: In this observational cohort study, we have followed up the 76 individuals who tested positive for SARS-CoV-2 infection by real-time reverse transcriptase-polymerase chain reaction (RT-qPCR) for 16 weeks (post-enrolment) to record the periodic changes in titre, concentration, clinical growth and persistence of naturally developed SARS-CoV-2 antibodies. We collected serum samples from these individuals for 16 weeks with a frequency of weekly and fortnightly during each follow-up and tested them in two CLIA-based platforms (Abbott Architect i1000SR and Roche Cobas e411) for testing SARS-CoV-2 antibodies both qualitatively and quantitatively. RESULTS: We recorded the antibody magnitude of these individuals 10 times between September 2020 and February 2021. We found a waning of antibodies against nucleocapsid antigen protein but not a complete disappearance by the end of 16 weeks. Out of 76 cases, 30 cases (39.47%) became seronegative in qualitative assay, although all the sera samples (100%) remained positive when tested in quantitative assay. CONCLUSION: The lower persistence of anti-nucleocapsid SARS-CoV-2 antibody may not be the exact phenomenon as those cases were still seropositive against spike protein and help in neutralising the virus. |*COVID-19[MESH] |*Spike Glycoprotein, Coronavirus[MESH] |Antibodies, Viral[MESH] |Antibody Formation[MESH] |Humans[MESH] |Immunoglobulin G[MESH] |Nucleocapsid[MESH] |SARS-CoV-2[MESH]IgG antibody response against nucleocapsid and spike protein post-SARS(epmc).pdf DeepDyve Pubget Overpricing